Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
BUSINESS
Espha’s Velcade AG Wins Approval for Mantle Cell Lymphoma
Daiichi Sankyo Espha said on October 30 that its authorized generic version of Velcade (bortezomib), Bortezomib for Injection 3 mg “DSEP”, has gained approval for an additional indication of mantle cell lymphoma.The proteasome inhibitor is already approved in Japan for…
To read the full story
Related Article
- Velcade Generics Widen Labels to Mantle Cell Lymphoma
December 18, 2025
- Authorized Generics for Edirol, Vesicare, Vegamox, and More in December Listing
December 10, 2021
- DS Espha to Launch Velcade Authorized Generic in December
August 24, 2021
BUSINESS
- High-Dose Uptravi Now Available: Nippon Shinyaku
May 21, 2026
- Myelofibrosis Med Inrebic to Go on Sale June 1: Recordati Japan
May 21, 2026
- Fuji Plans July Launch for Japan’s 1st Simponi, Ranmark Biosimilars
May 21, 2026
- Sanofi Eyes Double-Digit Annual Growth for Japan Vaccine Business: Exec
May 20, 2026
- Takeda Hit with Massive Damages Verdict in US Amitiza Antitrust Case
May 20, 2026
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…